A view of the booth of Bayer AG at an expo in Shanghai. TANG YANJUN/CHINA NEWS SERVICE German life sciences company Bayer AG is confident about the rapidly developing Chinese pharmaceutical market ...

German pharmaceutical company Bayer (BAYRY) said on Wednesday it has entered into a global license agreement with China’s Suzhou Puhe BioPharma Co. for its oral drug candidate targeting cancer ...

"This is another significant milestone for Bayer Pharmaceuticals in China and further strengthens our strategic presence in Beijing," said Sebastian Guth, chief operating officer of Bayer ...

The Bayer China Academic Collaboration Award aims to foster close partnerships with prestigious Chinese universities by recognizing and supporting distinguished scholars for their outstanding ...

Chalk it up to “volume-based procurement in China that weighed on price and volumes,” not to mention a Xarelto patent expiration in Brazil, Bayer’s chief financial officer, Wolfgang Nickl ...

A staffer displays a glucose continuous monitoring system at the booth of Bayer at the 4th China International Import Expo (CIIE) in east China's Shanghai, Nov. 7, 2021. [Photo/Xinhua] Bayer ...

Bayer’s network of Co.Lab life sciences incubators has expanded once again with the announcement of a new site in Shanghai, China, that will focus on oncology cell and gene therapies (CGT).

Bayer AG’s copanlisib was approved in China for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. It is the first indication ...

China's National Medical Products Administration (NMPA) approved Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) and Orion Corporation's oral drug Nubeqa, in combination with docetaxel, to treat patients with ...

The Bayer China Academic Collaboration Award aims to recognise and support distinguished scholars with outstanding achievements in life sciences, medical science as well as drug research and ...